Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 12-2012 | 09-2012 | 06-2012 | 03-2012 | 12-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 24 | 13 | 32 | 81 | 166 |
| Receivables | N/A | N/A | N/A | 106 | 8 |
| TOTAL | $107 | $328 | $543 | $238 | $282 |
| Non-Current Assets | |||||
| PPE Net | 189 | 67 | 73 | 75 | 87 |
| Other Non-Current Assets | 30 | 29 | 29 | 29 | 31 |
| TOTAL | $219 | $96 | $102 | $104 | $118 |
| Total Assets | $326 | $425 | $645 | $342 | $400 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,252 | 1,474 | 2,563 | 1,751 | 1,041 |
| Accrued Expenses | 382 | 394 | 630 | 657 | 453 |
| TOTAL | $2,576 | $2,945 | $4,386 | $3,183 | $2,218 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,960 | 1,103 | 2,465 | 2,792 | 2,876 |
| Deferred Revenues | N/A | N/A | N/A | 13 | 33 |
| Other Non-Current Liabilities | 5,305 | 2,825 | 68 | 63 | 57 |
| TOTAL | $8,272 | $3,937 | $2,544 | $2,865 | $2,944 |
| Total Liabilities | $10,848 | $6,882 | $6,930 | $6,047 | $5,162 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 669 | 578 | 567 | 586 | 550 |
| Common Shares | 22 | 20 | 20 | 19 | 16 |
| Retained earnings | -63,899 | -58,564 | -56,608 | -54,783 | -51,741 |
| Other shareholders' equity | -224 | -198 | -482 | -482 | -730 |
| TOTAL | $-10,522 | $-6,458 | $-6,285 | $-5,706 | $-4,762 |
| Total Liabilities And Equity | $326 | $425 | $645 | $342 | $400 |